Senseonics Expands Eversense CGM Commercialization Efforts

Senseonics Moves Forward with Eversense CGM Commercialization

In an exciting development for the diabetes management sector, Senseonics Holdings, Inc. (NYSE: SENS) recently announced a strategic partnership through a Memorandum of Understanding. This collaboration paves the way for Senseonics to take over the commercialization and distribution of the Eversense 365 continuous glucose monitoring (CGM) system from Ascensia Diabetes Care.

Transition of Responsibilities

Since 2020, Ascensia has been the exclusive distributor for Eversense products. However, following the agreement, Senseonics will assume all responsibilities related to sales and marketing for the Eversense 365 beginning January 1, 2026. Until then, Ascensia will provide transitional support to facilitate a smooth transition while Senseonics leverages this opportunity to establish itself solidly in the marketplace.

New Leadership for Commercial Growth

Another significant component of this transition is the appointment of Brian Hansen as the new Chief Commercial Officer of Senseonics effective January 1, 2026. Hansen's expertise in the diabetes care industry, particularly from his previous role at Tandem Diabetes Care and as President of CGM at Ascensia, positions him to lead Senseonics effectively during this major transition.

Strategic Investment for Eversense Growth

As the demand for innovative diabetes management solutions, like the Eversense system, continues to rise, this internalization of the commercialization efforts is crucial. The leadership at Senseonics believes that having dedicated control over commercialization efforts will lead to better responsiveness to market demands, allowing for a more tailored product offering.

The Evolution of the Eversense Product

With Eversense recognized as the pioneer of long-term continuously monitoring systems, the focus now shifts to holistic brand growth. Senseonics anticipates that by directly managing its commercial channels, it can enhance patient outreach and improve overall product availability. This strategy is expected to bolster revenue and profit margins by minimizing the need for shared profits with Ascensia.

Financial Insights and Outlook

In connection with this transition, Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million. This funding is aimed at bolstering the commercial organization as they adapt to new operational realities. As they implement these changes, Senseonics is projecting gross margins to improve significantly, forecasting a rise to 50% in 2026 and more than 70% at scale.

Looking Ahead: Revenue Projections

For the full year ahead, Senseonics estimates that the global net revenue for 2025 could range between $34 million and $38 million, as they focus on enhancing their patient base and increasing penetration in a competitive market. This growth is expected to be driven by the rollout of Eversense 365 and could see a significant uptick in the latter half of the year.

Investor Relations and Future Plans

To keep stakeholders informed of these developments, Senseonics is hosting a conference call to discuss these transitions and financial outlook on September 4, 2025. This event will provide investors with the opportunity to gain insights directly from the company’s leadership regarding the future of Eversense and its wider strategy in the diabetes management arena.

About Senseonics and Eversense

Senseonics Holdings, Inc. is revolutionizing diabetes management with its continuous glucose monitoring solutions. The Eversense® 365 is notable for its long-term monitoring capabilities, providing users with essential glucose data directly to their smartphones. These innovative systems support individuals with diabetes, enabling them to make informed decisions regarding their health.

Conclusion: A New Chapter for Senseonics

This transition marks an exciting new chapter in the journey of Eversense and Senseonics as a whole. By bringing the commercialization efforts in-house, Senseonics aims to innovate further and expand the reach of its life-changing diabetes management solutions.

Frequently Asked Questions

What is the significance of the Memorandum of Understanding?

The Memorandum of Understanding allows Senseonics to take over the commercialization and distribution of Eversense 365, enhancing operational efficiency and market responsiveness.

Who will lead commercial efforts at Senseonics?

Brian Hansen will be stepping in as Chief Commercial Officer starting January 1, 2026, bringing valuable experience to the role.

What financial support has Senseonics secured?

Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million to support its commercial organization.

When is the expected revenue growth for Senseonics?

Senseonics estimates a global net revenue of approximately $34 million to $38 million for the full year of 2025, with growth expected primarily in the latter half of the year.

How does Eversense differentiate itself in the market?

Eversense is recognized as the first implantable CGM system that provides continuous glucose monitoring for an entire year, setting it apart in the diabetes care market.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.